<DOC>
	<DOC>NCT00504959</DOC>
	<brief_summary>This extension study will investigate the long-term safety and tolerability of multiple intravitreal injections of ranibizumab administered to patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration who have been previously treated in either of the two ongoing ranibizumab studies CRFB002A2302 (EXCITE) or CRFB002A2303 (SUSTAIN</brief_summary>
	<brief_title>Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization, Pathologic</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Completion of 12month treatment period of study CRFB002A2302 (EXCITE) or CRFB002A2303 Concurrent participation in another clinical trial, i.e. use of other investigational drugs</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Age-related macular degeneration (AMD),</keyword>
	<keyword>choroidal neovascularization (CNV),</keyword>
	<keyword>vascular endothelial growth factor (VEGF)</keyword>
</DOC>